January 24, 2017
Novocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in Noble Capital Markets’ 13th Annual Investor Conference on Jan. 31, 2017, in Boca Raton, Florida. Ashley Cordova, Novocure’s Vice President of Finance and Investor Relations, will speak on behalf of the company and address questions from… Read More
learn more
January 19, 2017
Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
Globally, nearly 800 medical institutions can prescribe Optune to glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)– Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune® to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable,… Read More
learn more
January 10, 2017
Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics
1,091 active patients at Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015 January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial-stage oncology company developing a proprietary therapy for solid tumors, will provide a business update… Read More
learn more
January 10, 2017
Novocure to Report Fourth Quarter and Full Year 2016 Financial Results
January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it will report financial results for the fourth quarter and full year 2016 on Thursday, Feb. 23, 2017, before the open of U.S.-based financial markets. Novocure management will host a conference call… Read More
learn more
